Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI–IT/MS, (1)H, (13)C and (1)H–(1)H COSY NMR

A new impurity was detected during high performance liquid chromatographic (HPLC) analysis of eslicarbazepine acetate active pharmaceutical ingredient. The structure of unknown impurity was postulated based on liquid chromatography mass spectrometry using electrospray ionization and ion trap analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Saji, Paul, Saroj Kumar, Joshi, Subhash Chandra, Kumar, Vineet, Agarwal, Ashutosh, Vir, Dharam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2014
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761219/
https://www.ncbi.nlm.nih.gov/pubmed/29403898
http://dx.doi.org/10.1016/j.jpha.2013.08.004
Descripción
Sumario:A new impurity was detected during high performance liquid chromatographic (HPLC) analysis of eslicarbazepine acetate active pharmaceutical ingredient. The structure of unknown impurity was postulated based on liquid chromatography mass spectrometry using electrospray ionization and ion trap analyzer (LC/ESI–IT/MS) analysis. Proposed structure of impurity was unambiguously confirmed by synthesis followed by characterization using (1)H, (13)C nuclear magnetic resonance spectrometry (NMR), (1)H–(1)H correlation spectroscopy (COSY) and infrared spectroscopy (IR). Based on the spectroscopic and spectrometric data, unknown impurity was characterized as 5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl propionate.

Ejemplares similares